BioCentury - Aug. 6 Quick Takes: Sanofi gains FDA approval for Pompe therapy
Malattia di Pompe, via libera europeo all'uso di avalglucosidasi alfa come nuovo potenziale standard di cura - AboutPharma
Sanofi's enzyme replacement therapy available on NHS to Pompe disease patients - PMLiVE
Lumizyme | The Pompe Registry
Sanofi stock rises on licensing deal with Maze for Pompe disease drug | Seeking Alpha
Sanofi Finds Way to Maze Therapeutics to Get Its Next Pompe Disease Drug - MedCity News
Sanofi Genzyme goes to Phase III with Neuromuscular Disease
Sanofi signs agreement worth up to $750m for Maze's Pompe disease drug
Sanofi terminates deal to exclusively license Maze Therapeutics Pompe disease drug
Sanofi extends its Pompe range with first Nexviazyme OK | pharmaphorum
FDA approves Sanofi's Nexviazyme for Pompe disease treatment
Sanofi Italia on X: "La nostra ricerca sulle malattie rare non si ferma: sono 39 le presentazioni che terremo in questi giorni al @WORLDSymposia 2022 a San Francisco. Tra queste, anche nuovi
Sanofi Secures FDA Nod in Late-Onset Pompe Disease | BioSpace
U.S. FDA approves another Sanofi drug for rare muscle disorder Pompe disease | Reuters
FDA approves Sanofi's Nexviazyme for late-onset Pompe disease - Drug Discovery and Development
Sanofi: forte crescita delle vendite nel 2021 - Tecnomedicina
Sanofi Aventis – GM IMPIANTI
MeetSanofi | Malattia di Pompe, la qualità della vita passa anche dal cibo e dalla tecnologia
Sanofi drops acquisition of Maze's Pompe Disease drug after FTC challenge - PharmaLive
Sanofi US on X: "Have you heard of #Pompe disease? Just knowing the symptoms of this #RareDisease could help reduce the time to diagnosis. Share with the hashtag #GreaterThanPompe to raise awareness
Sanofi pumps up its Pompe portfolio with Maze deal | Evaluate
FDA aprueba Nexviazyme® de Sanofi Genzyme, una nueva e importante opción de tratamiento para la enfermedad de Pompe
